SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Xencor (XNCR)
An SI Board Since January 2014
Posts SubjectMarks Bans Symbol
136 22 0 XNCR
Emcee:  scaram(o)uche Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
111I wonder how the REGN bispecific compares to the returned Ab? Really tough to gBiotech Jim-1/7/2019
110Novartis hands back CD3 X CD20scaram(o)uche-1/7/2019
109ASH updates..... mgnx...... "enrolled 31 patients at the recommended Phscaram(o)uche-12/4/2018
108MTD not reached, but hasn't been a stroll in park for some patients to date.scaram(o)uche-12/3/2018
107Xencor's quarterly revenue growth is NEGATIVE 9.3%.......SELL it!!! [graphiKyleLenn-3/16/2018
106Xencor Doses First Patient in Phase 1 Study of XmAb®18087 MONROVIA, Calif. Lance Bredvold-2/23/2018
105A break of 22.63 could move it up to 26.43. [graphic]hollyhunter-12/5/2017
104"Greatly attenuated" effect on platelets with sq 7195 Will be quite uscaram(o)uche-11/7/2017
103Sounds like they will not take 7195 forward independent of a partner. Janssen/Cscaram(o)uche111/7/2017
102Might be worth listening to the quarterly call, just starting. Discussion of Igscaram(o)uche-11/7/2017
101ncbi.nlm.nih.gov (Just to give everyone a view of what is happening in literatuscaram(o)uche111/5/2017
100CSL/JNJ anti-CD123 bites dust... endpts.comscaram(o)uche-10/17/2017
99CEO said they designed their CD3/CD123 - 14045 - to be somewhat less potent, so tuck-1/23/2017
98Hey, Lance! The specificity of antibodies is determined by two identical portioscaram(o)uche112/7/2016
97Apparently everybody does want a good Fc whatever that might be. Your posts oftLance Bredvold-12/6/2016
96Company did not need money, and got this out the door, today, while again tradinscaram(o)uche112/6/2016
95You're welcome. Great sleuthing by that crew at twitter. Not one of the lescaram(o)uche-9/21/2016
94Thanks for the pointer. stock doesnt seem to be getting hammered by the news. mopgcw-9/21/2016
93pointer from @ADC_drugs........ immunogen.com (says "Expect IMGN632 in 16scaram(o)uche-9/21/2016
92keep looking through that same thread at twitter, and you'll find a pointer scaram(o)uche-9/21/2016
91>> CD123 is a fave marker << JNJ/Genmab project suspended, severe ascaram(o)uche-9/21/2016
90CD123 is a fave marker, extending back to mid-90s. Believe that phase I resultsscaram(o)uche-9/14/2016
89This is a very nice wrinkle..... "mid single-digit tiered royalties for worscaram(o)uche-9/7/2016
88Both of today's PRs emphasized their perceived advantages, using full lengthscaram(o)uche-6/28/2016
87$150 million upfront, Fc's are the "product"........ Xencor Annouscaram(o)uche-6/28/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News